While EGFR inhibitors are generally thought to be efficacious primarily in lung cancers expressing EGFR with activating mutations, a substantial number of patients who are negative for these mutations derive some modest benefit from treatment, suggesting that WT EGFR can support tumor growth [36]. This evidence concerns the gene EGFR and lung carcinoma.